Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Bought Deal
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(56)
•••
Comment by RalphRalphon Feb 17, 2021 5:49pm
153 Views
Post# 32588387

RE:RE:RE:RE:RE:RE:Bought Deal

RE:RE:RE:RE:RE:RE:Bought Deal
You're making large assumptions about royalty levels.  Upfront cash doesn't always mean a lower royalty percent - depends on how much demand there is for the asset and for partnership.  Look at the recent Arrowhead deal with Takeda as an example. 
 
A bought deal that includes warrants at this stage in the game is not a desirable thing. 

 


WalkOverTheStrt wrote: Have to disagree with this, any upfront capital from a partnership would come with it a lower royalty %, shareholders get diluted either upfront like this or during negotations with upfront cash option... we don't excape the pound of flesh.... 
I'd rather have mgmt have zero need for any partnership funds in order to have the strongest position in negoations going fwd for the largest markets / buyout...


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities